Small-Cell Lung Cancer Specialty Channel

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/04/2024

Stephanie Holland ;

According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...

According to results from a...

11/04/2024

Oncology

News

Adjuvant Durvalumab Significantly Extends Survival Among Patients With Limited-Stage Small Cell Lung Cancer

10/23/2024

Stephanie Holland ;

According to results from the phase 3 ADRIATIC trial, adjuvant durvalumab significantly extended survival compared to placebo among patients with limited-stage small cell lung cancer.

According to results from the...

10/23/2024

Oncology

Conference Coverage

Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

10/09/2024

Stephanie Holland ;

According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.

According to interim analysis...

10/09/2024

Oncology

Videos

Tarlatamab Plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung Cancer

10/08/2024

Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.

Sally Lau, MD, discusses results...

10/08/2024

Oncology

Conference Coverage

Addition of Novel IgG1 Monoclonal Antibody to Chemoimmunotherapy Shows Promise in Extensive-Stage Small Cell Lung Cancer

10/01/2024

Stephanie Holland ;

According to interim analysis results from a phase 2 study, the addition of BMS-986012, a novel IgG1 monoclonal antibody, to carboplatin plus etoposide and nivolumab demonstrated promising efficacy and safety as first-line treatment for...

According to interim analysis...

10/01/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

According to phase 1/2 study...

09/09/2024

Oncology

Conference Coverage

Addition of Anlotinb to Durvalumab Maintenance Improved Survival Results Among Patients With Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.

Results from the phase 2 DURABLE...

09/09/2024

Oncology

Conference Coverage

Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer

09/05/2024

Allison Casey ;

According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...

According to updated results...

09/05/2024

Oncology

News

Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer

09/04/2024

Stephanie Holland ;

According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.

According to extended follow-up...

09/04/2024

Oncology

News

Conference Coverage

Tarlatamab Showed Promising Efficacy For Previously Treated Patients With/Without Brain Metastases With Small-Cell Lung Cancer

06/18/2024

Stephanie Holland

Subgroup analysis results from the DELLphi-301 study found that tarlatamab showed promising efficacy with favorable benefit-risk profile among patients with previously treated small-cell lung cancer, regardless of baseline brain metastases.

Subgroup analysis results from...

06/18/2024

Oncology

Conference Coverage

Efficacy, Safety of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy Among Patients With Extensive-Stage Small-Cell Lung Cancer

06/11/2024

Stephanie Holland

According to results from a phase 2 study, adebrelimab plus chemotherapy and sequential thoracic radiotherapy demonstrated promising efficacy and safety among patients with extensive-stage small-cell lung cancer.

According to results from a...

06/11/2024

Oncology

News

FDA Grants Accelerated Approval to Tarlatamab for Patients With Extensive-Stage Small Cell Lung Cancer

05/17/2024

Stephanie Holland

Based on results from the DELLphi-301 trial, the FDA has granted accelerated approval to tarlatamab for patients with extensive-stage small cell lung cancer.

Based on results from the...

05/17/2024

Oncology

News

Addition of Tiragolumab to Atezolizumab Plus Chemotherapy Did Not Improve Survival Outcomes Among Patients With Extensive-Stage Small-Cell Lung Cancer

01/09/2024

Stephanie Holland ;

Results from the phase 3 SKYSCRAPER02-study found tiragolumab added to atezolizumab plus carboplatin and etoposide did not significantly improve progression-free survival or overall survival among patients with previously untreated...

Results from the phase 3...

01/09/2024

Oncology

News

Addition of Berzosertib to Topotecan Did Not Improve PFS Among Patients With Relapsed Small Cell Lung Cancer

11/13/2023

Stephanie Holland ;

According to results from a phase 2 study, the addition of berzosertib to topotecan significantly improved overall survival but did not improve progression-free survival among patients with relapsed small cell lung cancer.

According to results from a...

11/13/2023

Oncology

News

Prophylactic Cranial Irradiation Improved Survival Outcomes Compared to Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer

09/21/2023

Stephanie Holland ;

Results of a comparison study demonstrated PCI was associated with greater overall survival and progression-free survival improvement compared to consolidative TRT among patients with extensive-stage small cell lung cancer previously treated...

Results of a comparison study...

09/21/2023

Oncology

News

First-Line Serplulimab Plus Chemotherapy Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

12/02/2022

Derek Cowsert ;

Patients with extensive stage small-cell lung cancer experienced prolonged progression-free and overall survivals when treated with serplulimab plus chemotherapy, compared to placebo plus chemotherapy.

Patients with extensive stage...

12/02/2022

Oncology

News

Certain Tumor Microenvironment Factors Associated With Durable Clinical Benefit From Immune Checkpoint Inhibitor Therapy for Extensive Stage SCLC

10/12/2022

Derek Cowsert ;

A retrospective study identified multiple factors associated with durable clinical benefit in patients with extensive stage small-cell lung cancer being treated with immune checkpoint inhibitors and chemotherapy.

A retrospective study identified...

10/12/2022

Oncology

News

Anlotinib Proves Safe and Effective as First- and Second-Line Treatment for SCLC

08/09/2022

Derek Cowsert ;

A recent real-world observational study found anlotinib exhibited promising efficacy and safety for patients with small-cell lung cancer.

A recent real-world...

08/09/2022

Oncology

News

Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease

06/16/2022

Derek Cowsert ;

Study findings reveal treatment with stereotactic radiosurgery was associated with equitable survival outcomes vs whole brain radiotherapy for intracranial metastatic disease in patients with SCLC.

Study findings reveal treatment...

06/16/2022

Oncology

Interactive Features

Quiz

Quiz: Standard of Care for Patients With Small Cell Lung Cancer

11/30/2022

What is the current treatment for patients with small cell lung cancer?

What is the current treatment...

11/30/2022

Oncology

Quiz

True or False: Median PFS of patients with SCLC with inflamed tumors receiving ICI and chemotherapy double that of patients with noninflamed tumors.

11/09/2022

According to a retrospective study, how did the median PFS of patients with extensive stage SCLC receiving immune checkpoint inhibition and chemotherapy who had inflamed tumors compare to those patients with noninflamed tumors?

According to a retrospective...

11/09/2022

Oncology

Quiz

True or False: PD-1 and PD-L1 inhibitors can be utilized as treatment in almost all stages of small-cell lung cancer (SCLC)?

09/30/2022

Can PD-1 and PD-L1 inhibitors be used to treat small-cell lung cancer in addition to non-small cell lung cancer?

Can PD-1 and PD-L1 inhibitors be...

09/30/2022

Oncology

Quiz

Quiz: Durvalumab Plus Concurrent Chemoradiation Among PD-L1 Positive Patients With SCLC

08/29/2022

Among patients with limited-stage SCLC, did patients in the PD-L1 positivity group of a phase 2 study published in the European Journal of Cancer experience longer PFS and OS vs patients who were PD-L1 negative when treated with durvalumab...

Among patients with...

08/29/2022

Oncology

Quiz

Quiz: Current First-Line Standard of Care for Extensive-Stage SCLC

07/25/2022

What treatment option in addition to platinum-based chemotherapy has become the current standard of care in the first-line setting for patients with extensive-stage small-cell lung cancer?

What treatment option in...

07/25/2022

Oncology

Quiz

Quiz: Does Next-Generation BAP1 Therapy Inhibit SCLC Cell Viability and Tumor Growth?

07/20/2022

According to study findings, does the recently developed therapy targeting SCLC BAP1 activity iBAP-II inhibit SCLC cell viability and tumor growth in vivo?

According to study findings,...

07/20/2022

Oncology

Quiz

Quiz: Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease

07/14/2022

According to systemic review and meta-analysis, when does stereotactic radiosurgery not prolong overall survival compared to whole brain radiotherapy in treatment of patients with small-cell lung cancer and intracranial metastatic disease?

According to systemic review and...

07/14/2022

Oncology

Quiz

Quiz: Which Combination Improved Overall Survival Among Patients With SCLC in the CAPSTONE-1 Trial?

05/24/2022

Findings from the CAPSTONE-1 trial found that the addition of which of the following drugs to chemotherapy significantly improved overall survival in patients with extensive-stage SCLC?

Findings from the CAPSTONE-1...

05/24/2022

Oncology

Test Your Knowledge

Quiz: Do Functional Biomarkers Play a Vital Role in SCLC Therapy?

02/24/2022

True or false: Discovering and targeting functional biomarkers for SCLC is crucial in understanding the molecular basis underlying tumorigenesis to better assist in improving clinical treatment.

True or false: Discovering and...

02/24/2022

Oncology

Test Your Knowledge

Quiz: Which Additional Therapy Improves Chemotherapy Experience in Previously Treated ES-SCLC?

02/18/2022

Which of the following treatments are administered to patients with previously treated ES-SCLC, prior to topotecan, to improve the experience of receiving chemotherapy?

Which of the following...

02/18/2022

Oncology

Recent News

Conference Coverage

Tarlatamab Showed Promising Efficacy For Previously Treated Patients With/Without Brain Metastases With Small-Cell Lung Cancer

06/18/2024

Stephanie Holland

Subgroup analysis results from...

06/18/2024

Oncology

Conference Coverage

Efficacy, Safety of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy Among Patients With Extensive-Stage Small-Cell Lung Cancer

06/11/2024

Stephanie Holland

According to results from a...

06/11/2024

Oncology

News

FDA Grants Accelerated Approval to Tarlatamab for Patients With Extensive-Stage Small Cell Lung Cancer

05/17/2024

Stephanie Holland

Based on results from the DELLphi-301 trial, the FDA has granted accelerated approval to tarlatamab for patients with extensive-stage small cell lung cancer.

Based on results from the...

05/17/2024

Oncology

News

Addition of Tiragolumab to Atezolizumab Plus Chemotherapy Did Not Improve Survival Outcomes Among Patients With Extensive-Stage Small-Cell Lung Cancer

01/09/2024

Stephanie Holland ;

Results from the phase 3...

01/09/2024

Oncology

News

Addition of Berzosertib to Topotecan Did Not Improve PFS Among Patients With Relapsed Small Cell Lung Cancer

11/13/2023

Stephanie Holland ;

According to results from a...

11/13/2023

Oncology

News

Prophylactic Cranial Irradiation Improved Survival Outcomes Compared to Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer

09/21/2023

Stephanie Holland ;

Results of a comparison study...

09/21/2023

Oncology

News

First-Line Serplulimab Plus Chemotherapy Improves Survival Outcomes in Extensive-Stage Small Cell Lung Cancer

12/02/2022

Derek Cowsert ;

Patients with extensive stage...

12/02/2022

Oncology

News

Certain Tumor Microenvironment Factors Associated With Durable Clinical Benefit From Immune Checkpoint Inhibitor Therapy for Extensive Stage SCLC

10/12/2022

Derek Cowsert ;

A retrospective study identified...

10/12/2022

Oncology

News

Anlotinib Proves Safe and Effective as First- and Second-Line Treatment for SCLC

08/09/2022

Derek Cowsert ;

A recent real-world observational study found anlotinib exhibited promising efficacy and safety for patients with small-cell lung cancer.

A recent real-world...

08/09/2022

Oncology

News

Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Patients With SCLC and Intracranial Metastatic Disease

06/16/2022

Derek Cowsert ;

Study findings reveal treatment with stereotactic radiosurgery was associated with equitable survival outcomes vs whole brain radiotherapy for intracranial metastatic disease in patients with SCLC.

Study findings reveal treatment...

06/16/2022

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology